HMI-115
Phase 3Small molecule
HMI-115 is one of 47 small molecule programs targeting Endometriosis. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
Orilissa
AbbViePhase 3
IC-Green
PProvepharm SAS
Approved
Estrace
Novo NordiskApproved
Ketalar
AAultman Health Foundation
Approved
Flagyl
DDePuy Orthopaedics
Approved
Zocor
OOrganon and Co
Approved
Trelstar
OOncoVerity, Inc.
Approved
Implanon
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometriosis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HMI-115. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHope Medicine (Nanjing) Co., Ltd